Prevalence and Intervention of Hypomagnesemia in Users of Proton-pump Inhibitors (Privet)
Primary Purpose
Hypomagnesemia, Intestinal, With Secondary Hypocalcemia, Drug Induced Hypomagnesemia
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Inulin
Sponsored by
About this trial
This is an interventional treatment trial for Hypomagnesemia, Intestinal, With Secondary Hypocalcemia focused on measuring hypomagnesemia, hypocalcemia, inulin, FOS, PPI, proton-pump inhibitors
Eligibility Criteria
Inclusion Criteria:
- Chronic PPI use
- Hypomagnesemia
Exclusion Criteria:
- Uncontrolled diabetes
- Irregular use of the inulin fibers
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
No Intervention
Arm Label
Inulin
No Inulin
Arm Description
Intervention by inulin, max 20gr per day
Same Patients of arm inulin. Here the phase without inulin supplementation (own controls)
Outcomes
Primary Outcome Measures
Cases and controls: Mean serum Mg2+ treatment effect of inulin (composite measure)
Measured values at respective timepoints are denoted as means +/- SEM in mmol/L. The treatment effect is calculated by the overall mean change of serum Mg2+ during the two inulin treated phases (Days 0 - 14 and days 28 - 42) and expressed as mean +/- SEM.
Secondary Outcome Measures
Cases and controls: Mean serum Ca2+ treatment effect of inulin (composite measure)
Measured values at respective timepoints are denoted as means +/- SEM in mmol/L. The treatment effect is calculated by the overall mean change of serum Ca2+ during the two inulin treated phases (Days 0 - 14 and days 28 - 42) and expressed as mean +/- SEM.
Cases only: 24-hrs urine Mg2+ excretion without inulin at days 27/28
Measured values for respective timepoint is denoted as a mean +/- SEM in mmol/24hrs.
Cases only: 24-hrs urine Mg2+ excretion with inulin at days 41/42
Measured values for respective timepoint is denoted as a mean +/- SEM in mmol/24hrs.
Cases only: 24-hrs urine Ca2+ excretion without inulin at days 27/28
Measured values for respective timepoint is denoted as a mean +/- SEM in mmol/24hrs.
Cases only: 24-hrs urine Ca2+ excretion with Inulin at days 41/42
Measured values for respective timepoint is denoted as a mean +/- SEM in mmol/24hrs.
Cases and controls: General demographics of PPI users (Composite measure)
Demographical data, extracted from patient reports with relevant data such as age, sex, PPI-use and Duration and relevant comorbidities
Cases and Controls: Genetic screen of polymorphisms in the TRPM6 gene
Small PCR and Sanger sequencing of exons 26+27 of the gene TRPM6 (Mg2+ channel)
Full Information
NCT ID
NCT02518659
First Posted
June 26, 2015
Last Updated
August 5, 2015
Sponsor
Radboud University Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT02518659
Brief Title
Prevalence and Intervention of Hypomagnesemia in Users of Proton-pump Inhibitors
Acronym
Privet
Official Title
Inulin- a Potential Preventive Dietary Supplement Against PPI Induced Hypomagnesemia
Study Type
Interventional
2. Study Status
Record Verification Date
August 2015
Overall Recruitment Status
Completed
Study Start Date
February 2014 (undefined)
Primary Completion Date
February 2015 (Actual)
Study Completion Date
June 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Radboud University Medical Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Hypomagnesemia is a severe side effect of longterm use of all available proton-pump inhibitors (PPIH). It develops due to intestinal malabsorption of Mg2+.
This study investigates the application of dietary inulin fibers in users of proton-pump inhibitors with such a hypomagnesemia. To this end, repetitive short-term trials of 14 days of orally administered inulin, separated by a wash-out period of 14 days each were performed in cases of PPIH and controls. This study was not blinded or randomized.
Detailed Description
Hypomagnesemia due to PPI use (PPIH) has a low frequency, but is a difficult to control side effect in clinical practice. It develops over years and results in severe symptoms related to the hypomagnesemia. Due to the widespread use of PPIs, the real number of PPIH may be high. Currently, there is a lack of intervention strategies and no general treatment protocols for patients exist. It is generally anticipated that PPI-withdrawal and antacid replacement therapy is the only working method to recover patients from the hypomagnesemia. However, this frequently resulted in rebound of gastric acid related complaints.
The molecular mechanism of PPIH involves a reduction of Mg2+ absorption by the large intestine. Inulin fibers have been shown to have prebiotic properties. The intestinal microbiome ferments inulin and releases butyrate into the luminal compartment of the intestine. This results in acidification which enhances the uptake of Mg2+ and Ca2+ mediated by pH-sensitive ionchannels.Thus inulin may counteract PPI induced reduction of luminal protons and therefore reestablish normal Mg2+ absorption.
To this end cases with PPIH and controls underwent two 14 day trials of orally administered inulin under separated by wash-out periods of 14 days. During the experimental phase blood measures of electrolytes were monitored.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypomagnesemia, Intestinal, With Secondary Hypocalcemia, Drug Induced Hypomagnesemia
Keywords
hypomagnesemia, hypocalcemia, inulin, FOS, PPI, proton-pump inhibitors
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
21 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Inulin
Arm Type
Other
Arm Description
Intervention by inulin, max 20gr per day
Arm Title
No Inulin
Arm Type
No Intervention
Arm Description
Same Patients of arm inulin. Here the phase without inulin supplementation (own controls)
Intervention Type
Dietary Supplement
Intervention Name(s)
Inulin
Other Intervention Name(s)
Beneo Orafti Synergy1
Intervention Description
This is the Intervention
Primary Outcome Measure Information:
Title
Cases and controls: Mean serum Mg2+ treatment effect of inulin (composite measure)
Description
Measured values at respective timepoints are denoted as means +/- SEM in mmol/L. The treatment effect is calculated by the overall mean change of serum Mg2+ during the two inulin treated phases (Days 0 - 14 and days 28 - 42) and expressed as mean +/- SEM.
Time Frame
Cases and controls were followed for 56 days. Single measures of serum Mg2+ (in mmol/L) were performed at days 0, 14, 28,42 and 56.
Secondary Outcome Measure Information:
Title
Cases and controls: Mean serum Ca2+ treatment effect of inulin (composite measure)
Description
Measured values at respective timepoints are denoted as means +/- SEM in mmol/L. The treatment effect is calculated by the overall mean change of serum Ca2+ during the two inulin treated phases (Days 0 - 14 and days 28 - 42) and expressed as mean +/- SEM.
Time Frame
Cases and controls were followed for 56 days. Single measures of serum Ca2+ (in mmol/L) were performed at days 0, 14, 28,42 and 56.
Title
Cases only: 24-hrs urine Mg2+ excretion without inulin at days 27/28
Description
Measured values for respective timepoint is denoted as a mean +/- SEM in mmol/24hrs.
Time Frame
Collected 24-hrs urine samples are taken from each case at days 27/28. Samples were stored and measured within one week after day 56, the finalizing day of the respective participant.
Title
Cases only: 24-hrs urine Mg2+ excretion with inulin at days 41/42
Description
Measured values for respective timepoint is denoted as a mean +/- SEM in mmol/24hrs.
Time Frame
Collected 24-hrs urine samples are taken from each case at days 41/42. Samples were stored and measured within one week after day 56, the finalizing day of the respective participant.
Title
Cases only: 24-hrs urine Ca2+ excretion without inulin at days 27/28
Description
Measured values for respective timepoint is denoted as a mean +/- SEM in mmol/24hrs.
Time Frame
Collected 24-hrs urine samples are taken from each case at days 27/28. Samples were stored and measured within one week after day 56, the finalizing day of the respective participant.
Title
Cases only: 24-hrs urine Ca2+ excretion with Inulin at days 41/42
Description
Measured values for respective timepoint is denoted as a mean +/- SEM in mmol/24hrs.
Time Frame
Collected 24-hrs urine samples are taken from each case at days 41/42. Samples were stored and measured within one week after day 56, the finalizing day of the respective participant.
Title
Cases and controls: General demographics of PPI users (Composite measure)
Description
Demographical data, extracted from patient reports with relevant data such as age, sex, PPI-use and Duration and relevant comorbidities
Time Frame
at day 0
Title
Cases and Controls: Genetic screen of polymorphisms in the TRPM6 gene
Description
Small PCR and Sanger sequencing of exons 26+27 of the gene TRPM6 (Mg2+ channel)
Time Frame
DNA was extracted from blood, amplified and sequenced in average 2 months after bloodwithdrawal
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Chronic PPI use
Hypomagnesemia
Exclusion Criteria:
Uncontrolled diabetes
Irregular use of the inulin fibers
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
René Bindels, Professor
Organizational Affiliation
Radboud University Medical Center
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
22762246
Citation
Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther. 2012 Sep;36(5):405-13. doi: 10.1111/j.1365-2036.2012.05201.x. Epub 2012 Jul 4. Erratum In: Aliment Pharmacol Ther. 2012 Dec;36(11-12):1109.
Results Reference
background
PubMed Identifier
23756852
Citation
Lameris AL, Hess MW, van Kruijsbergen I, Hoenderop JG, Bindels RJ. Omeprazole enhances the colonic expression of the Mg(2+) transporter TRPM6. Pflugers Arch. 2013 Nov;465(11):1613-20. doi: 10.1007/s00424-013-1306-0. Epub 2013 Jun 12.
Results Reference
background
PubMed Identifier
12514257
Citation
Coudray C, Demigne C, Rayssiguier Y. Effects of dietary fibers on magnesium absorption in animals and humans. J Nutr. 2003 Jan;133(1):1-4. doi: 10.1093/jn/133.1.1.
Results Reference
background
Learn more about this trial
Prevalence and Intervention of Hypomagnesemia in Users of Proton-pump Inhibitors
We'll reach out to this number within 24 hrs